Top in cardiology: Menopause and CVD, aspirin bleeding risk

According to a presentation at the virtual Heart in Diabetes Conference, physicians should discuss CVD risk reduction by the time a woman hits menopause.

Another presentation from the meeting was about the risks and benefits of aspirin use for primary CVD prevention.

Read these and more top stories in cardiology below:

Menopause presents critical time for CVD risk reduction

Menopause can be a good time to start addressing CVD risk reduction even though it should be discussed way before then, according to a presentation at the virtual Heart in Diabetes Conference. Read more.

Bleeding risk, protective effects of aspirin for primary CVD prevention must be weighed

The current literature does not support the use of aspirin for primary prevention in patients with diabetes, and physicians must balance the benefits of prevention with the increased risk for major bleeding, according to a speaker. Read more.

Braunwald: SGLT2 inhibitors have influenced CV care regardless of diabetes status

Two paradigm shifts have established SGLT2 inhibitors as an important drug class to treat cardiac dysfunction and heart failure with reduced ejection fraction in patients with and without diabetes, according to a presentation. Read more.

AI can benefit care of patients with CVD, diabetes

Artificial intelligence has the ability to affect cardiovascular and diabetes care for both patients and clinicians, a presenter said. Read more.

Pollution confers cardiac structure, function abnormalities in Hispanic, Latino patients

Occupational exposures to vehicle exhaust, burning wood, metals and pesticides were linked to abnormal parameters of left ventricular and right ventricular systolic dysfunction in Hispanic and Latino participants, researchers found. Read more.